DEFEND-1, NCT00678886: Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): |
|
|
| Completed | 3 | 272 | US, Canada, Europe | otelixizumab infusion plus physician determined standard of care, monoclonal antibody, ChAglyCD3, anti-CD3, TRX4, placebo infusion plus physician determined standard of care | GlaxoSmithKline, Juvenile Diabetes Research Foundation | Diabetes Mellitus, Type 1 | 01/12 | 01/12 | | |
| Completed | 3 | 179 | Europe | Otelixizumab, ChAglyCD3, TRX4, monoclonal antibody, anti-CD3, Placebo | GlaxoSmithKline, Juvenile Diabetes Research Foundation | Diabetes Mellitus, Type 1 | 03/12 | 03/12 | | |
